BND-67 / Biond Biologics - LARVOL DELTA

BND-67: a novel immunotherapy targeting the CD28/PD-1 axis in T cells to overcome cancer resistance and transform relapse into long-term remission (SITC 2024) - "BND-67 is an efficient specific CD28-shedding inhibitor that generates significant T cell responses against tumor cells and surmount resistance to current immunotherapies, namely anti-PD-1. Preparations for a first-in-human clinical study with BND-67 are underway."

Clinical • Oncology • MMP13 • MMP2

CD28 shedding is a novel resistance mechanism to anti PD-1 therapy (AACR 2022) - "We report here the discovery of a potential novel resistance mechanism to anti-PD1 blockade involving the shedding of the CD28 receptor. This process occurs in the setting of cancer and was further reinforced by results observed in transgenic mice. Biond has generated BND-67, a therapeutic drug candidate for the inhibition of this novel regulatory mechanism."

Oncology • MMP13 • MMP2

Biond Biologics Announces Oral Presentation for BND-67, an Inhibitor of CD28 Shedding, a Potential Novel Resistance Mechanism to Anti PD-1 Therapy, at the American Association for Cancer Research (AACR) 2022 Annual Meeting (PRNewswire) - "Biond Biologics Ltd...announced...that the abstract on BND-67 was accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting...Soluble CD28 produced by this shedding mechanism was shown to counteract the efficacy of anti-PD-1 blocking antibodies in-vitro...Biond will present data demonstrating CD28-shedding process as a potential resistance mechanism to PD-1 therapies and will describe BND-67, an agent that can selectively and efficiently block this novel regulatory mechanism in cancer patients....In addition to Biond's BND-67 program, the company's Immuno-Oncology (I-O) pipeline also includes BND-35, an anti Ig-Like Transcript 3 (ILT3) antibody, an immune checkpoint inhibitor that inhibits the activity of suppressive myeloid cells."

Preclinical • Hematological Malignancies • Oncology